
    
      MEN16132 is a non-peptide bradykinin B2-receptor antagonist showing analgesic and
      anti-inflammatory activity in nonclinical osteoarthritis models. This study is being
      conducted as a dose finding study to determine the safety and efficacy of MEN16132, given as
      three doses/four treatment regimens in comparison to placebo, as well the time to onset and
      duration of effect.
    
  